Homology‑independent targeted insertion (HITI) enables guided CAR knock‑in and efficient clinical scale CAR‑T cell manufacturing
Overview
Describes a non-viral CRISPR/Cas9 HITI method for CAR knock-in. Primary T cells were cultivated in G-Rex® 24-well/6-well plates or G-Rex® 100M vessels.
What this paper found
Homology-independent targeted insertion (HITI) with CRISPR/Cas9 and nanoplasmid DNA placed an anti-GD2 CAR into the TRAC locus of primary human T cells and, on average, gave about threefold higher CAR-T cell yields than an HDR template with comparable insertion rates. Adding methotrexate-driven CEMENT selection of a DHFR-FS marker from day 3 raised purity to 86.6–91.4%, and at day 14 enriched cultures reached 80–85% CAR-positive cells. Clinical-scale runs with three donors produced doses of 5.5 × 10^8 to 3.6 × 10^9 CAR-positive T cells in a 14-day process. Average on-target copy number was 1.08, no off-target editing was detected, and knock-in cells matched virally transduced cells in phenotype, in vitro function and control of metastatic neuroblastoma in mice.
Note: Process development study: the scale-up runs were manufactured from healthy donor material, and antitumor activity was tested in a mouse model.
We have developed and optimized HITI/CEMENT, a new platform that allows precise genome engineering and enrichment of T cells. — Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G. Mancini, Gavin L. Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel, Christopher J. Fisher, Annie K. Brown, Ramya H. Tunuguntla, Shabnum Patel, Elena Sotillo, Crystal L. Mackall, Steven A. Feldman, Molecular Cancer
Study details
- Authors
- Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G. Mancini, Gavin L. Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel, Christopher J. Fisher, Annie K. Brown, Ramya H. Tunuguntla, Shabnum Patel, Elena Sotillo, Crystal L. Mackall, Steven A. Feldman
- Institution
- Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA · MaxCyte, Inc, Rockville, MD, USA · Integrated DNA Technologies, Inc, Coralville, IA, USA
- Journal
- Molecular Cancer
- Year
- 2023
- G-Rex® model(s)
- G-Rex®100M, G-Rex®24 Well Plate, G-Rex®6 Well Plate
- Cell type(s)
- CAR T Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
Primary human T cells were cultured in G-Rex® 24-well and 6-well plates or G-Rex® 100 M according to the manufacturer's instructions, with the culture volume expanded over time to hold the cell concentration. After large-scale electroporation with the GMP compatible CL1.1 assembly, cells rested for 30 minutes in G-Rex® 6-well plates before being transferred into the final G-Rex® vessels. For clinical-scale manufacturing, 1 × 10^9 enriched T cells per donor were activated with CD3/CD28 Dynabeads and cultivated in G-Rex®, and CAR-T cells were harvested on day 14.
Explore related
Full citation
Balke-Want H, Keerthi V, Gkitsas N, et al. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing. Mol Cancer. 2023;22(1):100.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.